<SEC-DOCUMENT>0001193125-17-170958.txt : 20170516
<SEC-HEADER>0001193125-17-170958.hdr.sgml : 20170516
<ACCEPTANCE-DATETIME>20170515185833
ACCESSION NUMBER:		0001193125-17-170958
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170515
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170516
DATE AS OF CHANGE:		20170515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HELIUS MEDICAL TECHNOLOGIES, INC.
		CENTRAL INDEX KEY:			0001610853
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			WY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55364
		FILM NUMBER:		17846583

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 400, 41 UNIVERSITY DRIVE
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
		BUSINESS PHONE:		215-809-2018

	MAIL ADDRESS:	
		STREET 1:		SUITE 400, 41 UNIVERSITY DRIVE
		CITY:			NEWTOWN
		STATE:			PA
		ZIP:			18940
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d384293d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>May&nbsp;15, 2017 (May&nbsp;15, 2017) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g384293g87k31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B><U>HELIUS MEDICAL TECHNOLOGIES, INC.</U> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><U>WYOMING</U></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><U>000-55364</U></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><U>36-4787690</U></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 400, 41 University Drive </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Newtown, Pennsylvania, 18940 </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (215)&nbsp;809-2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule&nbsp;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this
chapter). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company &#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act &#9746;
</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;7.01 Regulation FD Disclosure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;15, 2017, Helius Medical Technologies, Inc. (the &#147;Company&#148;) posted an updated corporate fact sheet to its website at
http://heliusmedical.com/index.php/investor-relations/overview, which the Company may use from time to time in communications or conferences. A copy of the corporate fact sheet is attached as Exhibit&nbsp;99.1 to this Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (this &#147;Report&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Report, including Exhibit&nbsp;99.1
hereto, is furnished pursuant to Item&nbsp;7.01 and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of
that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company&#146;s submission of
this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Report and Exhibit&nbsp;99.1 hereto contain forward-looking statements within the meaning of the federal securities laws. These forward
looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit&nbsp;99.1 and in the other reports of the Company filed with
the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d)&nbsp;Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Corporate Fact Sheet, dated May&nbsp;15, 2017</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>HELIUS MEDICAL TECHNOLOGIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: May&nbsp;15, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Joyce LaViscount</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Joyce LaViscount, Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d384293dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fact Sheet: May 15, 2017 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g384293g87k31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Developer of the Portable Neuromodulation Stimulator (PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>)
Therapy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Helius Medical Technologies is a United States-based medical device company developing and commercializing the PoNS<SUP
STYLE="font-size:85%; vertical-align:top">TM </SUP>Therapy platform, a powerful wearable direct current stimulation technology to treat movement and gait disorders in patients with traumatic brain injury (TBI) and chronic neurological disease. The
first targeted application of the PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> is for balance disorder tied to mild to moderate TBI. The US neurostimulation device market is forecast to grow to $4 billion in 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Features of the PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> therapy platform: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Proprietary non-invasive wearable platform for treating symptoms of neurological disease or trauma; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Direct impulses delivered to the brain and brainstem via disposable arrays placed on the tongue (razor blade), powered by wearable pulse generator (razor); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The mild to moderate TBI trial with PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> Therapy was deemed a non-significant risk trial by the FDA; we expect to report on results of this trial in early 2H2017;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Class II regulatory process (120-day timeline from submission to FDA decision), with expected regulatory clearance in 1H2018; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pilot studies support motor and gait disturbance correction, across a range of neurological conditions, including Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), and Cerebral Palsy (CP); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reimbursement framework for physical and cognitive therapy portion of treatment in place with commercial and government payers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Protected by over 40 patents including proprietary medical methods (5), as well as design and utility of therapeutic delivery mechanisms (35); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Potential opportunity for human performance improvement applications post medical therapy development. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Highlights: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Helius is led by an experienced
management team. CEO Phil Deschamps, CFO&nbsp;&amp; COO Joyce LaViscount and CMO Jonathan Sackier each bring over 30+ years of experience in Health Sciences industry with a focus on development and commercialization of healthcare products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company is nearing completion of a 120 patient double-blind, randomized, sham-controlled study of the safety and effectiveness of the PoNS<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> device for cranial nerve noninvasive neuromodulation in subjects with a chronic balance deficit due to mild to moderate TBI. The Company plans to submit for FDA, Health Canada and CE Mark and TGA
regulatory approval of the PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> device in 2H 2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to over $7 million in grants raised
by the inventors, the Company has raised $36 million in equity capital since June 2014, and has received $1.8 million in funding from the U.S. Army in support of PoNSTM clinical development, with a further $1 million expected later in 2017. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company filed a registration statement on Form S-3 in January 2017 establishing a $100 million shelf; $9.5
million was taken down in the February 2017 registered offering. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Helius shares are
currently traded on the Toronto Stock Exchange (symbol: HSM)&nbsp;&amp; Over-The-Counter Bulletin Board in the U.S. (symbol: HSDT) with a goal to be listed on a US national securities exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has received ISO 13485 Certification which permits submission to Health Canada, CE Mark in Europe and TGA in Australia. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Helius Medical&#146;s PoNS&#153; Therapy </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g384293g11b17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PoNS&#153; device delivers specially-patterned electrical stimulation developed to mirror nerve impulses to the brain
through 143-gold-plated electrodes on the mouthpiece which is placed on the tongue; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stimulation of the brain and brain-stem via cranial nerve innervation
of the tongue is hypothesized to encourage neuroplasticity, or a &#147;re-routing&#148;, enabling the damaged brain to compensate for lost function due to trauma or disease, by recruiting existing working neurons; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, when used in combination with specialized physical or cognitive therapy, has been shown to
improve symptoms of patients with chronic neurological symptoms caused by disease or trauma; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Relative to most neurological drug and device treatments,
shorter clinical timelines, fewer study subjects and a shortened regulatory pathway offer relatively lower-cost opportunities to bring new indications to market; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key near-term focus is the ongoing FDA registrational trial for PoNS&#153; Therapy for the treatment of balance deficit associated with mild to moderate TBI.
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investment Highlights for Helius Medical Technologies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>One of the few pure-play medical device company in the large and growing neuromodulation market. </B>The neuromodulation market is estimated at nearly $6
billion worldwide by 2020 and is expected to grow in the double digits on a percentage basis annually. Significant industry consolidation by large, diversified medical device companies has left few pure-play companies developing and commercializing
novel therapies. Differentiated technologies like the PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> device capture market share relatively quickly post-launch. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Helius has a number of compelling milestones. </B>The company has a goal to have its shares listed on a US national securities exchange, a critical
component in potentially broadening the US institutional investor base. Data from the 120 patient double-blind, randomized, sham-controlled trial in TBI is expected to read out in early 2H2017. Assuming FDA clearance, the 510(k)-de Novo to Class II
device classification could allow for commercial launch as early as 1H2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> Therapy could
play a unique role in the treatment paradigm for multiple neurological deficits. </B>The unique and non-invasive neuromodulation approach, in conjunction with physical or cognitive therapy, as well as pharmacotherapies, could allow for potential
broad applicability across a range of indications beyond TBI. Positive outcomes with PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> Therapy could reduce the cost of pharmaceutical and rehabilitation treatments for patients that are
incurred with today&#146;s care plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Flexible business model. If the PoNS<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> Therapy is approved
for commercialization, the combination of the wearable pulse generator and disposable mouthpiece could result in a recurring revenue stream. The service model is expected to launch in a clinic setting initially, with potential expansion to
home-based therapy care plan support model, with existing reimbursement for treatment. The de Novo device classification affords for relatively short clinical trials with a small number of subjects, translating to relatively low cost development to
expand into additional indications. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks are discussed
more fully in the &#147;Risk Factors&#148; section of our Transition Report on Form 10-K for the period ended December&nbsp;31, 2016, which we filed with the SEC on April&nbsp;3, 2017. These risks include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the Company&#146;s limited operating history; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company being dependent on the ability and expertise of its Chief Executive Officer, Chief Medical Officer and a very limited number of employees; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company having incurred losses since its inception and its anticipation that it will continue to incur substantial net losses for the foreseeable future and may never achieve or sustain profitability;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks relating to the Company requiring additional financing to carry out its plan of operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s independent registered public accounting firm having included an explanatory paragraph relating to the Company&#146;s ability to continue as a going concern in its report on the Company&#146;s audited
financial statements for the year ended December&nbsp;31, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s failure to maintain effective internal controls over financial reporting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the Company raising additional capital by issuing securities or through debt financing or licensing arrangements that may cause dilution to existing shareholders, restrict its operations or require the
Company to relinquish proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks concerning the Company only having one product candidate, which is still in development, and the Company not having obtained clearance from the United States Food and Drug Administration (the
&#147;<B>FDA</B>&#148;), CE Mark, TGA (Australia) or Health Canada with respect thereto; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s dependence on outside scientists and third-party research institutions for its research and development in order to be able to commercialize its product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that if the Company fails to obtain FDA clearance for commercialization of or otherwise fails to ensure that the PoNS&#153; device is available for purchase by the U.S. Government by December&nbsp;31, 2017, the
Company will be subject to significant risk of loss of data and proprietary rights and a US$2,000,000 contract penalty payable to A&amp;B pursuant to the Strategic Agreement with A&amp;B; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the risk that the Strategic Agreement with A&amp;B may be terminated; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the limited market awareness of the Company and its product; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the neuromodulation market being new and growing but undefined; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s PoNS&#153; technology being a new &#147;untested&#148; form of neurostimulation therapy and the medical community tending to be very conservative in adopting new therapies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">risks related to the Company needing to expand its products beyond its single product by commercializing new product candidates, and the Company not being able to do so in a timely fashion and at expected costs, or at
all; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">development by others of new or improved devices or products that may result in the Company&#146;s present and future products from becoming obsolete. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This fact sheet contains
forward-looking statements and forward-looking information as such terms are defined under applicable U.S. federal securities and Canadian securities legislation. All statements other than statements of historical fact contained in this fact sheet
constitute forward-looking statements and forward-looking information, including, without limitation, statements containing the words &#147;believe&#148;, &#147;may&#148;, &#147;plan&#148;, &#147;should&#148;, &#147;predict&#148;,
&#147;potential&#148;, &#147;will&#148;, &#147;estimate&#148;, &#147;continue&#148;, &#147;anticipate&#148;, &#147;intend&#148;, &#147;expect&#148;, &#147;seek&#148;, &#147;mission&#148;, &#147;goal&#148; and similar words, variations, expressions
or the negative thereof. Forward-looking statements are necessarily based on estimates and assumptions made by management of the Helius Medical Technologies, Inc. (&#147;Helius&#148;, &#147;we&#148; or the &#147;Company&#148;) in light of experience
and perception of historical trends, current conditions and expected future developments, as well as the factors management of the Company believes are appropriate. Forward-looking statements and information in this fact sheet include but are not
limited to statements relating to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential results of the Company&#146;s ongoing and planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Company&#146;s estimate of the size of the potential markets for its products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the estimated clinical, regulatory and commercial milestones and the timelines for achieving such milestones; </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the therapeutic benefits, effectiveness and safety of the Company&#146;s product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the Company will receive, and the timing and costs of obtaining, regulatory clearances in the U.S., Canada, EU and Australia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments and the regulatory environments in which the Company operates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">anticipated trends and challenges in the Company&#146;s business and the markets in which it operates. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such
statements reflect management of the Company&#146;s current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the
Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future
results, performance, or achievements that may be expressed or implied by such forward-looking statements, including, among others, those risks described in &#147;Risk Factors&#148; above and the risks described in our SEC filings, including our
Transition Report on Form 10-K for the period ended December&nbsp;31, 2016 and our other SEC filings from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This fact sheet speaks as of its
date and we, our advisors, and our and their affiliates and representatives undertake no obligation to update, revise or correct the information contained herein, except as required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Industry and Market Data </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This fact sheet contains
industry and market data that we obtained from independent industry publications. We have not independently confirmed this data and, although we believe it is generally reliable, it involves a number of assumptions and limitations, it is inherently
imprecise, and you are cautioned not to place undue reliance on it. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g384293g11b17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g384293g11b17.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@##UK6=0LM5LM-TS3[:[N+F":<FXNF@5%C:-3RL;DD
MF4=AT- %;^T_%O\ T ='_P#!O+_\C4 ']I^+?^@#H_\ X-Y?_D:@ _M/Q;_T
M ='_ /!O+_\ (U !_:?BW_H Z/\ ^#>7_P"1J #^U/%O_0!T?_P;R_\ R-0
M?VIXM_Z .C_^#>7_ .1J #^U/%O_ $ ='_\ !O+_ /(U "?VIXM_Z .C_P#@
MWE_^1J #^U?%O_0!T?\ \&\O_P C4 ']J^+?^@#H_P#X-Y?_ )'H /[5\6?]
M '1__!O+_P#(] !_:OBS_H Z/_X-Y?\ Y'H /[6\6?\ 0!T?_P &\O\ \CT[
M )_:WBS_ * .C_\ @WE_^1Z+ ']K>+/^@#H__@WE_P#D>BP!_:WBS_H Z/\
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M_P#X$C_XFCZO1_Y^?A_P0]K4_D#_ (2CQ#_T)\__ ($C_P")H^KT?^?GX?\
M!#VM3^0/^$H\0_\ 0GS_ /@2/_B:/J]'_GY^'_!#VM3^0/\ A*/$/_0GS_\
M@2/_ (FCZO1_Y^?A_P $/:U/Y _X2CQ#_P!"?/\ ^!(_^)H^KT?^?GX?\$/:
MU/Y _P"$H\0_]"?/_P"!(_\ B:/J]'_GY^'_  0]K4_D#_A*/$/_ $)\_P#X
M$C_XFCZO1_Y^?A_P0]K4_D#_ (2CQ#_T)\__ ($C_P")H^KT?^?GX?\ !#VM
M3^0/^$H\0_\ 0GS_ /@2/_B:/J]'_GY^'_!#VM3^0/\ A*?$'_0GS_\ @2/_
M (FCZO1_Y^?A_P $/:U/Y _X2CQ#_P!"?/\ ^!(_^)H^KT?^?GX?\$/:U/Y
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M?A_P0]K4_D#_ (2GQ!_T)\__ ($C_P")H^KT?^?GX?\ !#VM3^0/^$I\0?\
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MY _X2CQ#_P!"?/\ ^!(_^)H^KT?^?GX?\$/:U/Y _P"$H\0_]"?/_P"!(_\
MB:/J]'_GY^'_  0]K4_D#_A*?$/_ $)\_P#X$C_XFCZO1_Y^?A_P0]K4_D+G
MA[Q//K6H7EE<Z8;&:U +*TN\\]N@Q6=?#JE%24KIE4ZKFVFK6$U+_D?='_[!
M=[_Z-M*Y38U:8!0 4 !H 3- !0 4 )0 4 % "4""@!*8 : $H * $H * "@!
M* "@!* "@ H * "@!* "@ H * "@ H * "@ H 2@!: "@!* "@ H * "@ H
M2@ H P_ 9Q>>(?\ K]/\S7;B_AI^AST-Y>IV>:X#I#- !F@ R* #(H ,B@ S
M0 9H ,T &: #- !F@ R* "@""ZN%M;:2=D=Q&I8JO)P* ,V+Q+ICQ;I)3 P4
M.4D R!^% $MMX@TZYG\E)P)2VT(>YH &\1Z2CLANT#*<-[?6@"2#7-,NK@00
M72/*>BCZ9IB&IK=C).(HY2W!8L!P * !]=TZ-"S3X4#<25/2@"(>)-,^??<;
M-K%<,,9]Q0!HVEU!>6R7%N^^)_NMZTADV: #- !F@ S0 E !0 N: "@ H *
M#I0 F10 M !0 4 % !0 4  H X[PY_R/WB3_ (!7?7_W>F<U/^+(T-2_Y'W1
M_P#L%WO_ *-M*X#I-6F E !0 4 % "4 % "4 % !0 E A* "F &@!* "@!*
M"@ H * "@!* "@ H * "@!* "@ H * "@ H * "@ H * "@ H * $H * "@
MH * "@ H P? G_'YX@_Z_6_F:[<7\-/T.>AO+U.SK@.D* "@ H ,T &: #-
M!F@ H .E "$X% #&E1/O.!2;L"U!94;[K@_2A-,=K#MP'>F(CD>(QLLC#:>"
M#Z5/,D"U*/V;29&;,,!+#:?EZCTHYD5RLF2QT^.7SEMX1)V8+S1S(5B,V6E;
MG_<09?[V5ZT<Z"Q%:VUC'J<GE6\*>6H*E5Y&13YD3L7$L[5"2EO&,\'CM3N
MPZ988(-M&01CFBX7$ETW3Y6W26L#'U*T7 GB^SVL*Q1;(XUZ*. *5T- ;RW'
M69?SHNBN5CEN(G^[(#1="LT/WK_>%%Q"[E'>F PS(IY<"E=(%J1M?6R\&91^
M-+F17*QRW4+XVRJ?H:.9 XM$GF+C.X4<R)&M<1I]YP*.9#2N$<\<GW'!IW0W
M%H>7'KBF]%<D RYZBDG<!U.P!0 4 % !0 4 ** ..\.?\C]XD_X!7?7_ -WI
MG-3_ (LB_J7_ "/ND?\ 8+O?_1MI7 =)JTP"@ H 2@ H 2@ H 49+# +>U%[
M"LQJX9BJNC%>HW9(_*ES(KE'%'P?E(%',B&FAF".H-',,#QQ3N%["=*H-PJ1
MB4R0H&% !0 4 % "4 % !0 4 % !0 4 )0 4 % !0 4 % !0 4 % !0 4 %
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M; JQ0XR#VK5&+$H!!0 4 % !0 4 &* $H * "@ H * "@ H 2@ H * "@ H
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MPH$% !0 4 % !0 E !0 4 % !0 4 % !0 4 % !0 4 % Q#0 4 % !0 4 %
M!0 4 % !0 4 % !0(P? O_'WXA_Z_6_F:[<7\-/T.>AO+U.R-<!TD<T\=O$9
M9I$CC'\3' 'XT 1PWMI<+N@NHI5'4JX.* 'B>(Y E0D'!^84 *LT;?=D5AZA
MA0 Y75LA6#8ZX/2@!<T &0!0!&WS4;"LWL4Y]/L[@DRVD+GU9 34/4:E)'+Z
MKX?TZ>0K;6NSU:,XH43KA-F6/!UJ.6:8?\"_^M1RV-O:$-QX?TJS&96DS_=+
M9)_*GL',4WTVUR<6@A3LTS$D_111S#(/[)M(V+-:HZ_WIVVK_P!\CFEN%F/7
M38BO[BV!7'W88=H/XFC8>P@T7<@(TZW#?]-3N/Z52$07&AOL8,L2#'1%QC]:
M;6@N8S;7PQ;-*V1*I/=6Q6;B9RC<U7\"1^4IAU&="1G:_(J&C+V1C7G@^_MF
M5XF6YQW#$'\JGDL0Z5T68KN;31 )8GA=,=1WK1:',J;C(Z*35?/5'#9W 9IM
M7/1IZH5+E'(SBLWH;;&A#<JB85L+]::E8FUQS72 Y)Q[T.0*) VI^6?E>H;*
ML-_M%Y.*BXTD7+2W>=@<=.IJTC.;L:RA((MB_CCO5VL8VN-EN $&6S4W+4;&
M'>W"'/S#\32:+6@Q)4CA^\,GWICN:6E;&<?,*DRF]#I(W4@_,,5<3F97F*YR
M*NQ2-BW8O;HS<'%:&1+5 %( H #0 J]* ..\.?\ (_>)/^ 5WU_]WIG-3_BR
M+VJ?\CYI'_8+O?\ T;:5P'2:5, H 2BX"BD.X>V*K8EZG)^)[TRWJ6*'Y4^9
MS7%5>IZF&C9%FU0"S60\8!8'TP*F-[&E6Q\WWDN[5;N9%!S<,V.QY[U:,$65
M>.3<(G#IGDXP!_\ 6J6AC@QP6!R0=W)Z>OXU*W 0A8H\ME$7@MC.WN!]3ZTV
MA[%OPSH-QXQ\36VEH/+@^_,/^>2#KCW-:PB<]21],P00V5I#:6RA(($$:*.P
M%=*T.8?VZ8HL3<*JPP^E(!,T +0 =*!!^5 !^5 !B@!.E !0 4 % PH&% 7L
M% @H *!!0 4#"@ H * $H * "@04 % PH * "@ H *!&#X$_X_/$/_7ZW\S7
M;B_AI^AST-Y>IV0K@.DBN8$NK:6"09212I^AH Q)_"5A.<AI8V( )1L<  ?T
MH"PB>$K)!%B:?]TQ89(QSP: L3+X9LT0+%)+%CJ5QS^E %BPT6#3UE2*24K(
M0Q!<C'Y4 $\$<? :4X_Z;-_C6<G9@56\H9R9O^_S?XTN<M1N5);F&,'+2@?]
M=6_QHYKFJI7*%[J4403;)*%;K^];_&J12I)%>36],MU&6E+_ -U96)S^=67R
MI&7?>+_,8HD@B4#!2,@G\6[&HN-4S+&KRR9,6(Q_?SS_ -]'FIN;QIB6MXDD
MWEM*2V,G!VY_'K1N%DA9=7CMG($0!]<9H94;%>3Q$S=":B[1H^4KMKD@ZM@?
M6J4V9N*9"-7N+E=RN3SC JN=F?(D=%HLSN5\PC@?-FCG$T=*94D 4C QVJ><
MCE*LMNK9*-FG<+&=<6[XPZAQ[C-2%C)FTXR.3#(( !R".*I.PUH4)OMEGR^&
M7^\M4[,M"1ZI(."36;C8M(F%]))T-3:X7L7;6VFN" J,??I3Y"><W+2PBA7,
M\@8_W5/2GRV,W*Y=-\L0V(,*/[O2GS6)2N5I=52)2[M@]JALJUC*NM4FG!5#
MM7UI#L06UK]HD^?<PZDFJ0FK%Z&S2ZN51%^0<9H;(;L=';Z3!#$%).?4=JAL
MQ;N4[RVN;9#);.7([ XK2+,W$N:&+J^F E7:B=0QS6FX6L=<O JR!: "@ H
M* %% ''>'/\ D?O$G_ *[Z_^[TSFI_Q9%[5/^1\TC_L%WO\ Z-M*X#I-*F 4
M %3U&'0=JO8D@NKV&RMS-*^U<?+[FLI2L;4X79Y^;@7=^\O4,V2:XY.[/6I1
MLC1UN^&F>%;ZX+8V0D ^YZ5HEH95-SYVCE63UWCD^YIHQ'++(BD*Y53V!IV
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M%%#']U%"BN66YZ,-$=+X6T_[=J, E&07 (QV[UK&)C5J6T/80JQ*(T'R1_*
M.P]*ZHZ(\N<KLX'XI3[(--MU^[N+X-)FD=CR/5<*\W)P+?O2(9N^$+%+718$
M4!/,0SRL.I] 30)%+X@F-_!>FS3*&N3=%87/79W'N*8V>9[>0O/R\4"+ 0!:
M &,H/6@:('C Z$@4 R%HY%(  .>F:=["L-W8X:,47"PX,JC[K#_@5%PL()#R
M/,.!VI -^]R.O:@"U;:IJ%D0;:]GA/\ L-@4P-^Q^(OB2SPK72W"CM*@/ZT
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MND21\X4=<G..W2@"=-8OS9B9M/97\UD(P< #H<>] %G2;F\NK$2WL0AE8D!
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M9YW1L15\I"---;M7'*.A]Z8%B*_MI<8E'/:D!<5AC@Y%(8^@ H * "@ H *
M"@ H$8'@7_C[\0=O]-;^9KMQ?PT_0YZ&\O4T+V"Y&HW;Q:NL 95(C+_=K@.D
MH%[J5&MV\11F?H&20CWZ4("Q:2WPO8'GURWDC5R616^\I&!3%J;Z7UO-(4BF
MC=P,D*<D"IN.S(KB=RGR2!&]2,TKC469S:B\%QY,TBLKC*L%QTZBI;-%38[[
M?"WRLP!]*::ZCY&@8Q2+D,*EV-%=%&>SW D-2LD:1DT<5XBC<D*O.74#\Q06
MG<KLC17DG'RI'Q18T5A;*3_18RQQD9H!*Y;2=%&2X HN5RB_VFL8)C#,>Q/
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MM$,%CUK-NYVTH\AOV*J\9=LGBG%$UI7/5O#9!\.VK!-N<Y%=,=CRI[FI[51
MGI[4 8?B+PEIGB6/-PIANU&$N4&&_'U% 'E&O>!]8T)BSQ&XMNTT(H YB6,X
MVRHI'^V* ,^;2+*8DB$H?5#@4 49?#XZ0W1_X&*+ 4I-$OD;"JLH]CBE894F
MM+J+AK9QCOC-*PRJQ ^\2#Z$8HL#=AR*"#M*TK%)DKJ9  25/M04&UD5OFX
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MJ9)'J?6AF3U9M>'=.:YO(%(R,\_2M8(SJS]VQZ<<# '0<5T;'FB4 % !3 *
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MT42^43I=U\_I_I-G7F5/A9WT/XB//#;0INPK2G^^_2N0](J3J)!B-3(V/O=
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M>+?.@QJ-@OW;A.[ ?WJ8SK-!U^P\2Z-%JFFR9@<#=&>L3=U/H: -(<C/;^5
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MSXMH)_,?.2%' ^IJ2)5KF[8Z8MM%'YK>;)&, D?*OT%.QSR=R:X>&!<RG![
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M;0ACQC@J>HQ3 5+.*+=Y*["0%&T8P!T ]* #[&GF*\A:5QTW=OPI +/=16^
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MUH=+H#0:C:^<@*,AV21M]Z-AU4BMJ<+ETL5'$0YHZ/JNS['0A0!@# %=)8M
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M 6.&1Q"B[40G[HSSSWH"Q=BMHH261 &/4GD_G2&3?C0 4 % !0 4 % !0 4
M% !0 4 ,?BD!6<XK.0&?<2D&N:3-XQ(;6U>]D8MQ&.N*J$;L).QLPV<$2A5C
M7ZD9-=/+$QU)3!$1@QKCZ57+$-2%M/MF_P"68'TJ/9HKG:&'2[?L"/QH]F@]
MHQC:5#_>:E[-![1C?[(@]31[-![1DR:; @P 3]:%30G-C[:PM;--EO D2Y+8
M5<#)[U2@D9P48*T58EC@BBDDD2-$>0@NRK@L0,#/KQ5)6&HQ3;2W)*8PH *
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MJR HS19SCK7-RZFBG8TK.%8;=0!@GK73!61#=RQ6EA!0 4 % !0 4 '2@ H
M*!!0,* "@ H * %% ''>'/\ D?O$G_ *[Z_^[TSFI_Q9%[5?^1[TC_L%WO\
MZ.M*X#I-"F 4 % !0 E !0 4 % "4 % "4 )0 4 % !0 4 % "TP 4 +0 4
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M 'G>,/\ H":-_P"#>7_Y&H /.\8?] 31O_!O+_\ (U !YWC#_H":-_X-Y?\
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M ./4?[)YA^^\@QX[_P"H3_X]1_LGF'[[R#'CO_J$_P#CU'^R>8?OO(,>._\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % %+4[Z;3[3SX--N
M;]MV#%;-&& P?F_>.HQQZYYZ4I245=C2OH9NF>++2]T(:U>V\NCZ<R))'/J$
ML**ZMT.5=L=1][!YJYKD=I;DJ[;26Q?GU[1[6W@N+C5K**"X4/#(]PBK(IP
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g384293g87k31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g384293g87k31.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MMXALQN;Y5DE4D(1U!';Z]J /2]#T+0+5GOM)CB=9L8='\Q1@_P )YQS0!NT
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MQ%RY\P@G)QZ >E &'J7PXT6_G\V+S+3/5(L;/R(XH T=#\(:3H.'MXC+<?\
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4 H * "@ H * "@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
